Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038480 · ClinicalTrials.gov registry record · Phase 1
Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00038480 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 31 participants.
The verdict
NCT00038480, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe and well tolerated in HIV infected infants. This study will also determine the most effective dose of LPV/RTV for infants.
Interventions
- DRUG Lopinavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038480
The ClinicalTrials.gov registry entry for NCT00038480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lopinavir/Ritonavir is the first listed.
NCT00038480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038480 about?
NCT00038480 is a clinical study titled "Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants". The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe and well tolerated in HIV infected infants. This study will also determine the most effective dose of LPV/RTV for infants.
What is the current status of trial NCT00038480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00038480?
The interventions under investigation include: Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00038480?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.